High-affinity immunoglobulin epsilon receptor-bound allergen-specific immunoglobulin E (FcεRI-bound IgE)

The complex of allergen-specific Immunoglobulin E (IgE) bound to the high-affinity IgE receptor (FcεRI) on mast cells and basophils is the primary driver of allergic sensitization and subsequent inflammatory response. In this state, the Fc portion of IgE is anchored to the receptor, while the Fab regions are exposed and ready to capture specific allergens. Upon allergen encounter, the cross-linking of these IgE-FcεRI complexes triggers a signaling cascade that leads to the rapid release of inflammatory mediators like histamine and leukotrienes, resulting in symptoms of asthma, allergic rhinitis, and urticaria (1). Therapeutic intervention typically involves monoclonal antibodies like Omalizumab, which bind to free IgE to prevent its attachment to FcεRI, thereby gradually reducing the density of the bound complex on cell surfaces (2). Newer approaches include small molecule inhibitors that block the intracellular signaling (e.g., BTK inhibitors) initiated by the complex or disruptor molecules designed to actively displace IgE from the receptor (3). Understanding the dynamics of this complex is crucial for managing severe allergic conditions and developing next-generation immunotherapies (4).

Other names

FcεRI-IgE complexSensitized IgESurface-bound IgEAllergen-specific IgE-FcεRI complexMembrane-bound IgE on effector cells

Sequestration of free IgE to prevent receptor binding and subsequent downregulation of surface FcεRI, or inhibition of downstream signaling (e.g., BTK) following allergen-induced cross-linking.